Clinical review report: Ixekizumab (Taltz) (Eli Lilly Canada Inc.)
The objective of this review is to perform a systematic review of the beneficial and harmful effects of ixekizumab (Taltz) at the recommended dose for the treatment of adult patients with active psoriatic arthritis
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2018, August 2018
|
Edition: | Version: Final (with redactions) |
Series: | CADTH common drug review
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The objective of this review is to perform a systematic review of the beneficial and harmful effects of ixekizumab (Taltz) at the recommended dose for the treatment of adult patients with active psoriatic arthritis |
---|---|
Physical Description: | 1 PDF file (111 pages) illustrations |